GlassScriptPhysician profile
Thomas L Huffman
NPI 1396776761
$2,407.12
in general payments reported to CMS, 2019-2025
23 companies · $20.04 in 2025
The $20.04 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $324 · 2021: $505 · 2022: $330 · 2023: $608 · 2024: $269 · 2025: $20.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $483.88 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $401.56 | 2021-2023 | |
| Amgen INC. | $378.87 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $243.26 | 2021-2024 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $145.37 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $114.06 | 2019-2023 | Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.24 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $81.74 | 2019-2024 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $79.53 | 2024 | |
| Sanofi-Aventis U.S. LLC | $48.77 | 2019 | |
| Sunovion Pharmaceuticals INC. | $43.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.59 | 2019 | |
| Mylan Specialty L.P. | $40.41 | 2020-2023 | Yupelri |
| Radius Health, INC. | $30.98 | 2020 | |
| Jazz Pharmaceuticals INC. | $28.92 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $28.06 | 2022-2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $26.35 | 2020 | |
| Arbor Pharmaceuticals, INC. | $24.21 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $20.90 | 2024 | Abilify Asimtufii, Rexulti |
| Pfizer INC. | $20.18 | 2019 | |
| Abbott Laboratories | $14.03 | 2022 | |
| Exact Sciences Corporation | $13.64 | 2024 | Cologuard Collection Kit |
| Eisai INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.